1. Metabolic Enzyme/Protease
  2. Carbonic Anhydrase
  3. Dorzolamide

Dorzolamide (Synonyms: L671152; MK507)

Cat. No.: HY-B0109
Handling Instructions

Dorzolamide(L671152; MK507) is an anti-glaucoma agent, which is a carbonic anhydrase inhibitor.

For research use only. We do not sell to patients.

Dorzolamide Chemical Structure

Dorzolamide Chemical Structure

CAS No. : 120279-96-1

Size Price Stock
10 mg USD 70 Ask For Quote & Lead Time
50 mg USD 110 Ask For Quote & Lead Time
100 mg USD 170 Ask For Quote & Lead Time

* Please select Quantity before adding items.

Other In-stock Forms of Dorzolamide:

Other Forms of Dorzolamide:

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review


Dorzolamide(L671152; MK507) is an anti-glaucoma agent, which is a carbonic anhydrase inhibitor. Target: carbonic anhydrase (CA) Dorzolamide is a carbonic anhydrase inhibitor. It is an anti-glaucoma agent, and acts by decreasing the production of aqueous humour [1]. Glaucoma was induced in the right eye of adult Wistar rats by episcleral venous occlusion. One experimental group was administered dorzolamide 2%-timolol 0.5% combination eye drops, while the other experimental group was administered dorzolamide 2% eye drops. Control groups had surgery without drug administration. Drug application was initiated either 2 weeks before surgery (Group A), from the day of surgery (Group B), 2 weeks after surgery (Group C), or 4 weeks after surgery (Group D). RGCs were labeled by intratectal Fluorogold injections and counted from flat-mount preparations, and IOP was measured using Tonopen. Both dorzolamide-timolol combination and dorzolamide, when applied topically, significantly reduced IOP and improved RGC densities in experimental eyes when compared to control eyes. Earlier initiation, as well as longer duration of drug application, resulted in higher RGC densities [2]. Clinical indications: Glaucoma; Ocular hypertension FDA Approved Date: 1995 Toxicity: Dizziness, headache, shortness of breath, slow heartbeat, severe asthma, cardiac arrest

Clinical Trial
Molecular Weight







O=S(C(S1)=CC2=C1S([[email protected]@H](C)C[[email protected]@H]2NCC)(=O)=O)(N)=O


Room temperature in continental US; may vary elsewhere.


Please store the product under the recommended conditions in the Certificate of Analysis.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2


DorzolamideL671152MK507L 671152L-671152MK 507MK-507Carbonic AnhydraseCarbonate dehydrataseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number *


Organization name *

Country or Region *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product name:
Cat. No.:
MCE Japan Authorized Agent: